The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for monoclonal antibody treatments bamlanivimab/etesevimab and Regeneron's casirivimab/imdevimab for the treatment of mild to moderate COVID-19 in patients with positive results of direct SARS-CoV-2 viral testing. Bamlanivimab and casirivimab/imdevimab are interchangeable.
Patients with positive COVID-19 results who are 12 years of age or older and who have had mild to moderate symptoms for less than 10 days are eligible to receive the treatment. Patients with any of the following indicators may benefit from the monoclonal antibody infusion:
- Age ≥ 65
- Body mass index (BMI) ≥ 25 (or for pediatrics BMI ≥ 85th percentile for age)
- Chronic kidney disease
- Immunosuppressive disease or receiving immunosuppressive treatment
- Poorly controlled hypertension
- Cardiovascular disease or Congenital Heart Disease
- Chronic obstructive pulmonary disease (COPD) or other respiratory diseases
- Sickle cell disease
- Neurodevelopmental disorders
- Medical-related technological dependence (i.e. tracheostomy, gastrostomy)
- Other medical condition or factor (i.e. race or ethnicity) that may place the patient at a higher risk for progression to severe COVID-19
Treatment is NOT authorized for patients who are:
- Hospitalized or require oxygen therapy due to COVID-19
- On chronic oxygen therapy who require an increase in baseline oxygen flow due to COVID-19
How to Screen a patient
MedStar Health Physicians
- Please use the MedConnect PowerForm (which will automatically pop up in a patient’s chart after a COVID-19 positive test) to properly indicate your patient’s symptom onset, degree of illness, date of COVID-19 testing, and underlying risk factors. A score of 1 or greater indicates your patient meets criteria for treatment. For patients tested outside of MedStar Health who report a positive COVID-19 result, the results of the test can be entered into MedConnect (see job aid here) and the monoclonal scoring form will then pop up as a chart alert for completion.
Please access our provider frequently asked questions here.
Managing Patient Expectations
Not all COVID-19 positive patients are eligible to receive this treatment. If a patient’s clinical condition changes between the referral and arrival at the infusion center, the patient may no longer be eligible for this treatment. Please discuss this with your patients.